These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

875 related items for PubMed ID: 23700065

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A, Zimmermann M, Reiter A, Gadner H, Odenwald E, Harbott J, Ludwig WD, Riehm H, Schrappe M.
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [Abstract] [Full Text] [Related]

  • 4. [Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].
    Koehler R, Bartram CR.
    Klin Padiatr; 2013 May; 225 Suppl 1():S40-4. PubMed ID: 23700054
    [Abstract] [Full Text] [Related]

  • 5. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
    Paganin M, Zecca M, Fabbri G, Polato K, Biondi A, Rizzari C, Locatelli F, Basso G.
    Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM, Oren H, Baytan B, Bengoa SY, Evim MS, Gözmen S, Tüfekçi O, Karapınar TH, Irken G.
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [The results of a multicenter trial of acute lymphoblastic leukemia treatment on ALL-MB 91/ALL-BFM 90m in children: analysis of efficacy and toxicity].
    Karachunskiĭ AI, Miakova NV, Rumiantseva IuV, Timakov AM, Makhortykh TZh, Fechina LG, Shamardina AV, Dudkin SA, Lebedev VV, Varfolomeeva SR, Timofeeva VN, Herold R, Stakelberg A, Henze G, Rumiantsev AG.
    Ter Arkh; 2007 Oct; 79(7):19-26. PubMed ID: 17802785
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
    Aricò M, Valsecchi MG, Rizzari C, Barisone E, Biondi A, Casale F, Locatelli F, Lo Nigro L, Luciani M, Messina C, Micalizzi C, Parasole R, Pession A, Santoro N, Testi AM, Silvestri D, Basso G, Masera G, Conter V.
    J Clin Oncol; 2008 Jan 10; 26(2):283-9. PubMed ID: 18182669
    [Abstract] [Full Text] [Related]

  • 15. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
    Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH, Venn NC, van den Berg H, de Bont ES, Maarten Egeler R, Hoogerbrugge PM, Kaspers GJ, Bierings MB, van der Schoot E, van Dongen J, Law T, Cross S, Mueller H, de Haas V, Haber M, Révész T, Alvaro F, Suppiah R, Norris MD, Pieters R.
    Leukemia; 2013 Jul 10; 27(7):1497-503. PubMed ID: 23407458
    [Abstract] [Full Text] [Related]

  • 16. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM, Ribera JM, Xicoy B, Morgades M, Oriol A, Tormo M, del Potro E, Debén G, Abella E, Bethencourt C, Ortín X, Brunet S, Ortega-Rivas F, Novo A, López R, Hernández-Rivas JM, Sanz MA, Feliu E, PETHEMA Group.
    Eur J Haematol; 2007 Feb 10; 78(2):102-10. PubMed ID: 17087744
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
    Henze G, v Stackelberg A, Eckert C.
    Klin Padiatr; 2013 May 10; 225 Suppl 1():S73-8. PubMed ID: 23700062
    [Abstract] [Full Text] [Related]

  • 19. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
    Schmiegelow K, Heyman M, Kristinsson J, Mogensen UB, Rosthøj S, Vettenranta K, Wesenberg F, Saarinen-Pihkala U, Nordic Society of Paediatric Haematology and Oncology (NOPHO).
    J Pediatr Hematol Oncol; 2009 Jun 10; 31(6):385-92. PubMed ID: 19648786
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.